Scholarlink

Introduction and Aim <p>Despite ESG's efficacy in promoting weight loss, data on its impact on body composition is limited. This study evaluated ESG's effectiveness in improving body composition and metabolic parameters over 6 and 12&#xa0;months using InBody analysis.</p> Methods <p>We prospectively analyzed patients with obesity (BMI &gt; 30&#xa0;kg/m<sup>2</sup> or &gt; 27 with comorbidities) who underwent ESG between August 2021 and May 2024. Body composition was assessed via bioelectrical impedance analysis (InBody 770™).</p> Results <p>Thirty-six patients (81% female, mean age 47.9 ± 13.4&#xa0;years, BMI 35.3 ± 5.6&#xa0;kg/m<sup>2</sup>) completed baseline assessment. Follow-up rates were 67% at 6&#xa0;months and 61% at 12&#xa0;months. ESG produced significant reductions in BMI (4.6 and 4.8&#xa0;kg/m<sup>2</sup>) and total body weight loss (13.4% and 13.5%) at both timepoints (p &lt; 0.001). Body fat percentage decreased by 4.7% at 6&#xa0;months, with truncal fat loss of 4.0&#xa0;kg comprising 32% of total weight loss. These improvements persisted at 12&#xa0;months (p &lt; 0.01). While skeletal muscle mass also declined, muscle loss represented only 13–17% of total weight loss.</p> Discussion <p>ESG achieves substantial weight loss with preferential fat reduction and favorable preservation of lean body mass over 12&#xa0;months, supporting its role in improving metabolic health.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of Endoscopic Sleeve Gastroplasty on Body Composition and Metabolism: An InBody Analysis

  • 期刊论文

  • 发表日期：

    2025年9月8日

查看全文
  • Ali Lahooti,
  • Zane Gouda,
  • Sean Rangwani,
  • Kate E. Johnson,
  • Qusai Al Zureikat,
  • Chino Aneke-Nash,
  • Adeyinka Adejumo,
  • Muhammad Usman Baig,
  • Dominque Gay,
  • Adam Buckholz,
  • Robert E. Schwartz,
  • Carolyn Newberry,
  • Kartik Sampath,
  • David Carr-Locke,
  • SriHari Mahadev,
  • Sonal Kumar,
  • Reem Z. Sharaiha

摘要

Introduction and Aim

Despite ESG's efficacy in promoting weight loss, data on its impact on body composition is limited. This study evaluated ESG's effectiveness in improving body composition and metabolic parameters over 6 and 12 months using InBody analysis.

Methods

We prospectively analyzed patients with obesity (BMI > 30 kg/m2 or > 27 with comorbidities) who underwent ESG between August 2021 and May 2024. Body composition was assessed via bioelectrical impedance analysis (InBody 770™).

Results

Thirty-six patients (81% female, mean age 47.9 ± 13.4 years, BMI 35.3 ± 5.6 kg/m2) completed baseline assessment. Follow-up rates were 67% at 6 months and 61% at 12 months. ESG produced significant reductions in BMI (4.6 and 4.8 kg/m2) and total body weight loss (13.4% and 13.5%) at both timepoints (p < 0.001). Body fat percentage decreased by 4.7% at 6 months, with truncal fat loss of 4.0 kg comprising 32% of total weight loss. These improvements persisted at 12 months (p < 0.01). While skeletal muscle mass also declined, muscle loss represented only 13–17% of total weight loss.

Discussion

ESG achieves substantial weight loss with preferential fat reduction and favorable preservation of lean body mass over 12 months, supporting its role in improving metabolic health.